📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Indegene to Acquire Two UK Entities for GBP 2.7 Million in Internal Restructuring
Indegene Limited is streamlining its corporate structure by acquiring 100% equity in two UK-based subsidiaries, DT Associates Research and Consulting Services and Trilogy Writing and Consulting, for a combined cash consideration of approximately GBP 2.7 million. This internal restructuring will bring both entities under Indegene Healthcare UK Limited. DT UK reported FY25 revenue of GBP 6.4 million, while Trilogy UK reported GBP 2.34 million. The transaction is expected to be completed by March 31, 2026, and is classified as a related party transaction conducted at arm's length.
Key Highlights
Acquisition of 100% stake in DT UK for GBP 2,001,000 and Trilogy UK for GBP 702,348
DT UK revenue declined to GBP 6.4 million in FY25 from GBP 9.2 million in FY24
Trilogy UK showed revenue growth, reaching GBP 2.34 million for the period ending March 2025
The move is primarily for internal restructuring to consolidate UK-based life science service operations
Total cash consideration for both acquisitions is approximately GBP 2.703 million
💼 Action for Investors
Investors should view this as a routine corporate cleanup to simplify the subsidiary hierarchy. No immediate impact on consolidated financials is expected as the entities were already part of the group.
Indegene Q3 FY26 Revenue Grows 30.8% YoY to INR 9,421 Mn; Large Deal Wins Boost Outlook
Indegene reported a robust Q3 FY26 with total revenue of INR 9,421 million, a 30.8% YoY increase, including 18.3% organic growth. The company successfully integrated BioPharm and reported an adjusted EBITDA margin of 18.5%, with plans to reach 20% in 6-8 quarters. Significant deal wins were highlighted, including a $20 million TCV contract and a $10 million annual revenue engagement. Customer metrics improved with $1M+ accounts rising to 52 and revenue per employee exceeding $70,000.
Key Highlights
Revenue increased 30.8% YoY to INR 9,421 million; organic growth was 18.3% YoY.
Adjusted EBITDA margin stood at 18.5%, up 30 bps QoQ despite acquisition-related costs.
Secured 7 large deals exceeding $1M ACV each, including a major $20M TCV biotech partnership.
$1M+ customer count grew by 12 to 52; active customers increased to 86.
Revenue per employee surpassed $70,000, driven by specialized AI-led platforms and domain expertise.
💼 Action for Investors
Maintain a positive outlook given the strong deal pipeline and organic growth momentum. Watch for EBITDA margin expansion towards the 20% target as acquisition synergies and large deals scale.
Indegene Q3 Revenue Jumps 31% YoY to ₹9,421 Million; Completes ₹9,146 Million BioPharm Acquisition
Indegene Limited reported a strong 30.8% YoY growth in revenue from operations, reaching ₹9,421 million for Q3 FY26. Net profit for the quarter stood at ₹1,029 million, showing stability despite the integration of the BioPharm acquisition which cost ₹9,146 million ($104 million). The company also announced the allotment of 13,332 equity shares under its RSU 2020 plan and reconstituted key board committees. The nine-month revenue for FY26 has reached ₹25,071 million, compared to ₹20,837 million in the previous year.
Key Highlights
Revenue from operations grew 30.8% YoY to ₹9,421 million in Q3 FY26.
Completed acquisition of BioPharm Parent Holding Inc. for ₹9,146 million ($104 million) on October 1, 2025.
Consolidated net profit for the quarter recorded at ₹1,029 million with an EPS of ₹4.29.
Allotted 13,332 equity shares pursuant to the RSU 2020 Plan.
Nine-month total income reached ₹25,683 million, up from ₹21,653 million YoY.
💼 Action for Investors
Investors should view the significant revenue growth and successful M&A integration as positive indicators of scale. Monitor the EBITDA margins in upcoming quarters to ensure the BioPharm acquisition is yielding the expected operational efficiencies.
Indegene Q3 FY26 Revenue Surges 30.8% YoY to ₹9,421 Mn; First $100M+ Revenue Quarter
Indegene reported a strong Q3 FY26 with revenue growing 30.8% YoY to ₹9,421 million, marking its first quarter exceeding $100 million in revenue. While adjusted EBITDA grew 15.7% YoY to ₹1,747 million, reported PAT remained relatively flat at ₹1,026 million due to one-time acquisition costs and higher non-cash amortization. The company successfully completed the acquisitions of BioPharm (US) and Warn & Co. (UK), which contributed to the growth in the Enterprise Commercial Solutions segment. Management highlighted record productivity with revenue per employee crossing the $70,000 annual mark, driven by AI integration.
Key Highlights
Revenue from operations grew 30.8% YoY to ₹9,421 million ($106.1 million).
Adjusted EBITDA rose 15.7% YoY to ₹1,747 million, though margins compressed slightly to 18.5%.
Active client base expanded to 86, with 52 clients now contributing over $1 million in annual revenue.
Cash and investments remain strong at ₹13,954 million even after acquisition-related outflows.
Revenue per employee reached an industry-leading $70,000+ annually due to AI-led productivity gains.
💼 Action for Investors
Investors should look past the transient PAT flatness caused by acquisition accounting and focus on the robust 30%+ top-line growth and increasing client mining. The company's ability to scale revenue per employee through AI suggests significant long-term operating leverage.
Indegene Q3 FY26: Revenue Surges 30.8% YoY, Crosses $100M Quarterly Milestone
Indegene reported a strong Q3 FY26 with revenue reaching INR 9,421 million, a 30.8% YoY and 17.1% QoQ increase, marking its first-ever $100 million+ revenue quarter. While Adjusted EBITDA grew 15.7% YoY to INR 1,747 million, Profit After Tax (PAT) remained flat at INR 1,026 million due to one-time acquisition costs and higher non-cash amortization. The company achieved an industry-leading revenue per employee of over $70,000 and successfully integrated two acquisitions, BioPharm and Warn & Co. Strong deal momentum continues with multiple new contracts exceeding $10 million in annual contract value.
Key Highlights
Revenue from operations grew 30.8% YoY to INR 9,421 million ($106.1 million).
Adjusted EBITDA stood at INR 1,747 million with margins expanding 30bps sequentially to 18.5%.
Revenue per employee (RPE) crossed $70,000, the highest in the industry according to management.
Significant deal wins including two contracts exceeding $10 million ACV and one $20 million TCV contract.
Completed strategic acquisitions of BioPharm (US) and Warn & Co. (UK) to expand high-value capabilities.
💼 Action for Investors
Investors should view the strong top-line growth and productivity metrics as a sign of competitive strength, while looking past the temporary PAT stagnation caused by acquisition-related accounting. Monitor the integration of new acquisitions for margin recovery in the coming quarters.
Indegene Q3 FY26 Revenue Grows 30.8% YoY to ₹9,421 Mn; PAT at ₹1,029 Mn
Indegene reported a strong 30.8% YoY growth in revenue from operations, reaching ₹9,421 million for the quarter ended December 31, 2025. While revenue grew 17% sequentially, Profit After Tax (PAT) remained relatively flat at ₹1,029 million compared to the previous quarter, and slightly down from ₹1,097 million in the year-ago period due to higher tax expenses and depreciation. A significant highlight is the consolidation of BioPharm Parent Holding Inc., acquired for ₹9,146 million, which is expected to bolster the company's digital marketing and AI capabilities. The nine-month performance shows a healthy 20.3% revenue growth and an 11.2% increase in PAT.
Key Highlights
Revenue from operations surged 30.8% YoY to ₹9,421 million in Q3 FY26.
Consolidated PAT for the quarter stood at ₹1,029 million, with 9M PAT rising 11.2% YoY to ₹3,214 million.
Completed the acquisition of BioPharm Parent Holding Inc. for ₹9,146 million (USD 104 million) on October 1, 2025.
Total expenses increased to ₹8,268 million, driven by higher employee benefits and depreciation following the acquisition.
Basic EPS for the quarter was ₹4.29, compared to ₹4.59 in the same quarter last year.
💼 Action for Investors
Investors should monitor the successful integration of the BioPharm acquisition and its impact on margins in the coming quarters. The strong top-line growth suggests robust demand for digital-led life sciences services, making it a positive watch for long-term growth.
Indegene Appoints Jill DeSimone and Neeraj Bharadwaj to Board of Directors
Indegene Limited has strengthened its Board of Directors with the appointment of Jill DeSimone and Neeraj Bharadwaj. DeSimone is a veteran in the life sciences industry with over 40 years of experience, notably leading the launch of the blockbuster drug Keytruda at Merck. Bharadwaj, a Senior Advisor at Carlyle Asia, brings extensive expertise in private equity, capital allocation, and inorganic growth. These appointments are aimed at enhancing corporate governance and providing strategic oversight as Indegene scales its technology-led commercialization services for global biopharma companies.
Key Highlights
Jill DeSimone brings 40+ years of life sciences leadership, including her role as President of U.S. Oncology at Merck.
Neeraj Bharadwaj, a Senior Advisor at Carlyle Asia, joins with deep expertise in private equity and capital allocation.
DeSimone led the successful global launch of Keytruda, Merck's flagship oncology product.
The appointments focus on strengthening governance and supporting Indegene's technology-led modernization of life sciences.
💼 Action for Investors
The addition of high-caliber global leaders to the board is a positive signal regarding Indegene's commitment to governance and global expansion. Investors should view this as a strengthening of the company's strategic leadership and long-term value creation potential.
Indegene Appoints Former Merck Executive Jill Mary De Simone as Independent Director
Indegene Limited has announced the appointment of Ms. Jill Mary De Simone as an Additional Director (Non-Executive Independent Director) for a three-year term effective January 22, 2026. Ms. De Simone is a high-profile biopharmaceutical executive who previously served as the President of U.S. Oncology at Merck and held leadership roles at Teva and Bristol Myers Squibb. Her expertise in global healthcare commercialization and AI applications is expected to strengthen Indegene's strategic governance. The appointment is subject to shareholder approval and will run through January 21, 2029.
Key Highlights
Appointment of Ms. Jill Mary De Simone as Non-Executive Independent Director for a 3-year term.
Ms. De Simone previously served as President of U.S. Oncology at Merck with full P&L responsibilities.
The term is effective from January 22, 2026, to January 21, 2029, pending shareholder approval.
She brings specialized expertise in oncology, life sciences commercialization, and AI in healthcare.
The appointee has no familial or professional relationship with existing directors of the company.
💼 Action for Investors
Investors should view this as a positive governance move that adds significant global industry expertise to the board. No immediate action is required as this is a routine but high-quality leadership addition.
Indegene Completes Internal Restructuring with EUR 329k Acquisition of Trilogy Canada
Indegene Limited has announced an internal restructuring where its US subsidiary, Indegene, Inc., acquired 100% of Trilogy Writing & Consulting Inc. (Canada) for EUR 329,014. The target company, which specializes in medical writing, was previously a subsidiary of Indegene's German unit. Trilogy Canada has shown strong growth, with turnover increasing from CAD 369,636 in 2022 to CAD 892,361 in 2024. This move is designed to streamline the company's global corporate structure and was conducted on an arm's length basis.
Key Highlights
Acquisition of 100% equity in Trilogy Writing & Consulting Inc. (Canada) for a cash consideration of EUR 329,014
Target company turnover grew by approximately 141% over two years, reaching CAD 892,361 in 2024
The transaction is an internal restructuring moving the Canadian entity under the US-based subsidiary
Trilogy Canada specializes in medical writing services within the healthcare industry
The deal was signed and completed on December 31, 2025
💼 Action for Investors
As this is an internal restructuring of existing subsidiaries, there is no impact on consolidated financials. Investors should monitor if this streamlining leads to better operational efficiency in the North American market.
Indegene Appoints Neeraj Bharadwaj as Independent Director; Allots 1.49 Lakh ESOP Shares
Indegene Limited has announced the appointment of Mr. Neeraj Bharadwaj as a Non-Executive Independent Director for a five-year term starting January 25, 2026. Mr. Bharadwaj is a highly qualified professional with an MBA from Harvard and a BS from Wharton, bringing extensive experience in private equity and strategic leadership. Alongside this appointment, the board approved the allotment of 149,635 equity shares under the company's ESOP and RSU 2020 plans. These developments reflect a strengthening of the company's governance framework and continued execution of employee incentive schemes.
Key Highlights
Appointment of Mr. Neeraj Bharadwaj as Independent Director for a 5-year term effective January 25, 2026.
Mr. Bharadwaj brings global expertise with an MBA from Harvard University and a BS from the University of Pennsylvania (Wharton).
Allotment of 149,635 equity shares approved under ESOP Plan 2020 and RSU Plan 2020.
The director appointment is subject to shareholder approval through a Postal Ballot process.
The appointee has significant experience in private equity and investment management across diverse sectors.
💼 Action for Investors
The addition of a high-caliber independent director with private equity expertise is a positive signal for corporate governance. Investors should view this as a move to strengthen strategic oversight as the company scales.
Indegene Appoints Neeraj Bharadwaj as Independent Director for 5-Year Term
Indegene Limited has announced the appointment of Mr. Neeraj Bharadwaj as a Non-Executive Independent Director for a five-year term starting January 25, 2026. Mr. Bharadwaj brings significant expertise from his background in private equity and investment management, holding degrees from UPenn and Harvard. The appointment is subject to shareholder approval via postal ballot. Additionally, the board approved share allotments under the company's ESOP and RSU 2020 plans to employees.
Key Highlights
Appointment of Mr. Neeraj Bharadwaj as Non-Executive Independent Director for a 5-year term.
Term effective from January 25, 2026, through January 24, 2031, subject to shareholder approval.
Mr. Bharadwaj holds an MBA from Harvard and has extensive experience in private equity and strategic leadership.
Board also approved the allotment of shares under the ESOP Plan 2020 and RSU Plan 2020.
💼 Action for Investors
Investors should view this as a positive step towards strengthening corporate governance and strategic oversight. No immediate action is required, but the addition of a director with a private equity background may influence future capital allocation strategies.